Overview

A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious anterior uveitis
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Lux Biosciences, Inc.
Criteria
Inclusion Criteria:

- Documented history of non-infectious anterior, anterior and intermediate- or
panuveitis

- Currently uncontrolled uveitis for a minimum of 2 weeks despite use of oral and/or
topical corticosteroid,or subjects who are intolerant of local corticosteroid therapy
due to the development of an ocular hypertensive response or subjects for whom oral
corticosteroid is contraindicated.

- Grade of 2+ or higher for anterior chamber cells at time of enrollment

- Considered by the investigator to require corticosteroid-sparing therapy.

- Subjects not planning to undergo elective ocular surgery during the study

Exclusion Criteria:

- Uveitis of infectious etiology

- Presence of an ocular toxoplasmosis scar

- An immune suppression regimen that includes an alkylating agent within the previous 90
days